159820-24-3 Usage
Description
[3,5-Bis(trifluoromethyl)phenyl]methyl(methyl)amine is a chemical compound that features a phenyl group with two trifluoromethyl substituents at the 3 and 5 positions, a methyl group attached to the central carbon atom of the phenyl group, and an amine group connected to the methyl group. [3,5-Bis(trifluoromethyl)phenyl]methyl(methyl)amine is known for its strong electron-withdrawing properties due to the trifluoromethyl groups and its amine functionality, making it a valuable reagent for a variety of chemical transformations. The presence of the phenyl group also allows for aromatic chemistry and substitution reactions, contributing to its versatility and importance in organic chemistry.
Uses
Used in Pharmaceutical Industry:
[3,5-Bis(trifluoromethyl)phenyl]methyl(methyl)amine is used as an intermediate in the synthesis of various pharmaceutical compounds due to its unique structural features and reactivity. The strong electron-withdrawing nature and amine functionality enable the creation of a wide range of drug candidates with potential therapeutic applications.
Used in Chemical Synthesis:
In the field of chemical synthesis, [3,5-Bis(trifluoromethyl)phenyl]methyl(methyl)amine serves as a key building block for the creation of complex organic molecules. Its electron-withdrawing properties and amine group facilitate various chemical transformations, making it a useful reagent for the development of new compounds with specific properties and applications.
Used in Material Science:
[3,5-Bis(trifluoromethyl)phenyl]methyl(methyl)amine is also utilized in material science for the development of novel materials with unique properties. [3,5-Bis(trifluoromethyl)phenyl]methyl(methyl)amine's structural characteristics and reactivity can be harnessed to create materials with enhanced performance in areas such as electronics, coatings, and adhesives.
Used in Research and Development:
[3,5-Bis(trifluoromethyl)phenyl]methyl(methyl)amine is frequently employed in research and development settings to explore new reaction pathways, study the effects of electron-withdrawing groups on molecular properties, and develop new synthetic methods. Its versatility and reactivity make it an essential tool for advancing the field of organic chemistry and related disciplines.
Check Digit Verification of cas no
The CAS Registry Mumber 159820-24-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,9,8,2 and 0 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 159820-24:
(8*1)+(7*5)+(6*9)+(5*8)+(4*2)+(3*0)+(2*2)+(1*4)=153
153 % 10 = 3
So 159820-24-3 is a valid CAS Registry Number.
159820-24-3Relevant articles and documents
Bifunctional Br?nsted Base Catalyst Enables Regio-, Diastereo-, and Enantioselective Cα-Alkylation of β-Tetralones and Related Aromatic-Ring-Fused Cycloalkanones
Urruzuno, I?aki,Mugica, Odei,Oiarbide, Mikel,Palomo, Claudio
supporting information, p. 2059 - 2063 (2017/02/15)
The catalytic asymmetric synthesis of both α-substituted and α,α-disubstituted (quaternary) β-tetralones through direct α-functionalization of the corresponding β-tetralone precursor remains elusive. A designed Br?nsted base-squaramide bifunctional catalyst promotes the conjugate addition of either unsubstituted or α-monosubstituted β-tetralones to nitroalkenes. Under these reaction conditions, not only enolization, and thus functionalization, occurs at the α-carbon atom of the β-tetralone exclusively, but adducts including all-carbon quaternary centers are also formed in highly diastereo- and enantioselective manner.
NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS
-
Page/Page column 70; 71, (2013/09/12)
The present invention relates to a compound according to formula (A) wherein n is 1 or 2; R1 and R2 are independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, CD3 or halogen; R3 is hydrogen, C(=O)OR7 or C1-4 alkyl optionally substituted with hyd
TACHYKININ RECEPTOR ANTAGONISTS
-
Page 27-28, (2010/02/10)
The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.